VC-backed Allena debuts IPO
Newton, Massachusetts-based Allena Pharmaceuticals, a developer of treatments for patients with rare and severe metabolic and kidney disorders, has raised about $75 million for its IPO after pricing its over 5.3 million share at $14 per share. The stock began trading November 2, 2017 on the NASDAQ under the ticker symbol "ALNA." Credit Suisse, Jefferies and Cowen are the lead underwriters. Allena's investors included Frazier Healthcare, Bessemer Venture Partners, HBM Partners, Fidelity and Partner Fund Management.
2 November 2017•2 mins read
